title: Fluvoxamine as a sigma-1 receptor agonist improved cognitive impairments in a patient with schizophrenia.
authors.forename: Masaomi
authors.initials: M
authors.lastname: Iyo
authors.forename: Yukihiko
authors.initials: Y
authors.lastname: Shirayama
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Watanabe
authors.forename: Mihisa
authors.initials: M
authors.lastname: Fujisaki
authors.forename: Ryosuke
authors.initials: R
authors.lastname: Miyatake
authors.forename: Goro
authors.initials: G
authors.lastname: Fukami
authors.forename: Akihiro
authors.initials: A
authors.lastname: Shiina
authors.forename: Michiko
authors.initials: M
authors.lastname: Nakazato
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Shiraishi
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Ookami
authors.forename: Kenji
authors.initials: K
authors.lastname: Hashimoto
mesh_terms: D000328:Adult; D003072:Cognition Disorders / Q000188:drug therapy* / Q000209:etiology*; D005260:Female; D016666:Fluvoxamine / Q000627:therapeutic use*; D006801:Humans; D017480:Receptors, sigma / Q000819:agonists*; D012565:Schizophrenic Psychology; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D000097605:Sigma-1 Receptor
chemical_list: D016666:Fluvoxamine; D017480:Receptors, sigma; D017367:Selective Serotonin Reuptake Inhibitors; D000097605:Sigma-1 Receptor